Establishment of a cardio-oncology program in the Republic of Kazakhstan
Clicks: 5
ID: 323474
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
1.2
/100
5 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #97 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background/Introduction Despite well-established heart failure program in our country, structured cardio-oncology pathways and national registries are still lacking. This contributes to delayed recognition of therapy-related cardiovascular toxicity and advanced heart failure development in this group of patients. Purpose The aim of this study was to describe the initial set-up of a multidisciplinary cardio-oncology program and characterize patients with a history of cancer therapy and advanced heart failure referred to a specialized heart failure clinic, highlighting opportunities for earlier prevention and monitoring. Methods We performed a retrospective study of 45 patients (40 women, 5 men) with chronic heart failure and a prior oncological history followed up in a specialized heart failure clinic between 2018 and 2023. Descriptive statistics were used to summarize clinical characteristics and assess whether cardiovascular risk stratification and cardiotoxicity prevention had been performed before anticancer therapy. Results Median age of patients was 56.5 years, 76% of them had breast cancer. All patients had advanced heart failure (stage D; predominantly NYHA III–IV). No patients had documented baseline cardiovascular risk stratification or a structured cardiotoxicity prevention plan prior to initiation of systemic anticancer therapy. Two patients underwent Heart Mate 3 left ventricular assist device as destination therapy, underscoring the limited options once severe heart failure is established. At the time of analysis, 34 out of 45 patients were alive and continue to be followed in a specialized chronic heart failure clinic. Eleven patients died due to complications of chronic heart failure. Among the deceased patients, nine were women with a history of breast and ovarian cancer, and two were men with prostate and colorectal cancer. From 2026 a road map with initiating of cardio-oncology program across the country was launched. Conclusion(s) Implementation of structured cardio-oncology pathways, including standardized baseline risk assessment, longitudinal surveillance during and after cancer therapy, and timely cardioprotective treatment, may reduce the rate of terminal heart failure in its late presentation. Coordinated multidisciplinary team and a unified data base platform are essential to improve long-term cardiovascular outcomes in cancer patients.
| Reference Key |
openalex_W7172315823
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | R Abildayeva, A T Tauyekelova, A A Mukhamejanova |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.203
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.